Circulating Tumor Cell Detection in Lung Cancer: But to What End?

Hofman, Véronique; Heeke, Simon; Marquette, Charles-Hugo; Ilié, Marius; Hofman, Paul

doi:10.3390/cancers11020262

Cited by 22 publications

(20 citation statements)

References 108 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several strategies were applied to attempt to detect CTCs in lung cancer patients [74]. CTC surface anchor protein (such as CD326 EpCAM)-dependent isolation (e.g.…”

Section: Conventional Strategies To Detect Lung Cancer Ctcsmentioning

confidence: 99%

“…As a diagnostic marker of lung cancer, non-invasive and periodic detection of CTCs and CTECs may provide a compensatory choice to allow an effective early diagnosis of lung cancer [17,[92][93][94]. Multiple studies indicated that lung cancer CTCs could be detected several months prior to radiographic appearance of the primary lesion [74,95].…”

Section: Quantificationmentioning

confidence: 99%

See 1 more Smart Citation

Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer

Lin¹

2021

Lung Cancer - Modern Multidisciplinary Management

View full text Add to dashboard Cite

Risk stratification, prognostication and longitudinal monitoring of therapeutic efficacy in lung cancer patients remains highly challenging. It is imperative to establish robust surrogate biomarkers for identifying eligible patients, predicting and effectively monitoring clinical response as well as timely detecting emerging resistance to therapeutic regimens. Circulating tumor biomarkers, analyzed by liquid biopsy, are primarily composed of nucleic acid-based circulating tumor DNA (ctDNA) and an aneuploid cell-based category of circulating tumor cells (CTCs) and circulating tumor-derived endothelial cells (CTECs). Unlike ctDNA, cancer cells are the origin of all categories of various tumor biomarkers. Involvement of aneuploid CTCs and CTECs in tumorigenesis, neoangiogenesis, tumor progression, cancer metastasis and post-therapeutic recurrence has been substantially investigated. Both CTCs and CTECs possessing an active interplay and crosstalk constitute a unique category of cellular circulating tumor biomarkers. These cells concurrently harbor the intact cancer-related genetic signatures and full tumor marker expression profiles in sync with disease progression and therapeutic process. Recent progress in clinical implementation of non-invasive liquid biopsy has made it feasible to frequently carry out ctDNA analysis and unbiased detection of a full spectrum of non-hematologic circulating rare cells including CTCs and CTECs in lung cancer patients, regardless of variation in heterogeneous cell size and cancer cell surface anchor protein expression. In situ phenotypic and karyotypic comprehensive characterization of aneuploid CTCs and CTECs, in combination with single cell-based genotyping and improved ctDNA analyses, will facilitate and benefit multidisciplinary management of lung cancer.

show abstract

“…Several strategies were applied to attempt to detect CTCs in lung cancer patients [74]. CTC surface anchor protein (such as CD326 EpCAM)-dependent isolation (e.g.…”

Section: Conventional Strategies To Detect Lung Cancer Ctcsmentioning

confidence: 99%

Section: Quantificationmentioning

confidence: 99%

Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer

Lin¹

2021

Lung Cancer - Modern Multidisciplinary Management

View full text Add to dashboard Cite

show abstract

“…To date, numerous studies have shown the correlation between CTCs and cancer stages, invasiveness, and metastasis, including lung cancer [18,19]. However, for the reason that CTCs are extremely rare in NSCLC, whether CTCs could be detected in the peripheral blood of SPNs patients are quite unknown [20]. Therefore, collecting CTCs and analyzing characteristics of these CTCs would greatly improve the sensitivity and speci city of the lung cancer diagnosis, and provide proper subsequent therapeutic strategies.…”

Section: Introductionmentioning

confidence: 99%

The value of circulating tumor cells with positive centromere probe 8 in the diagnosis of small pulmonary nodules.

Liu

Chen

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Circulating cancer cells (CTCs) provide opportunities for early diagnosis and evaluation of cancer stage as a more acceptable non-invasive liquid biopsy. The advanced development and use of CTCs for diagnosis or prognosis just started in recent years.Methods: Fifty three patients, diagnosed as SPNs with a diameter less than 30 mm by CT examination, was enrolled for statistical analysis based on their CTCs level, CT examination features, serum tumor marker concentrations, and histopathological characteristics. Centromere probe 8 (CEP8) was utilized as a marker for CTCs determination. Results: The CTCs level was significantly different between malignant and benign SPNs, as well as between early (0/Ⅰa) and advanced (Ⅰb/Ⅱ/Ⅲ) stages of lung cancer. ROC analysis showed that the CTCs level had diagnostic effect on malignant SNPs. Combined use of CTCs and density feature of CT morphology further improve the overall diagnostic effect on the pTNM stage of these SPNs determined as lung cancer (≤Ia vs. >Ia stage) compared to use of these two markers solely, especially increased the diagnostic specificity. Moreover, in bigger, single, and solid SPNs based on CT morphology, the CTCs level significantly correlated with the malignant histopathology. Additionally, triple staining (CEP8, EpCAM and CKs) results using samples from 22 out of 53 patients showed that more CTCs was detected when CEP8 was used as a marker. Conclusions: The CTCs determined by CEP8 positive would be a potential adjuvant diagnostic marker for the malignance and stage of lung cancer for patients with SPNs.

show abstract

“…Although the concept of detecting cancer cells in blood sounds appealing, this method is limited by the fact that only a few CTCs can be found per 1x10 [92] have been shown to improve CTC capture to the point where there are enough tumour cells to be xenografted into mice and to study the tumour cells' molecular biology [93,94]. However, these studies mainly focuses on SCLC as they have high numbers of CTCs in blood with a strong ability to proliferate [93]. In comparison, NSCLC has much fewer cells in the blood and lower relative proliferative abilities, especially during early cancer stages.…”

Section: Circulating Tumour Cells (Ctcs)mentioning

confidence: 99%

“…In comparison, NSCLC has much fewer cells in the blood and lower relative proliferative abilities, especially during early cancer stages. This makes NSCLC CTCs much harder to capture and study [93].…”

Section: Circulating Tumour Cells (Ctcs)mentioning

confidence: 99%

Identification of clinically useful plasma miRNA as minimally invasive biomarkers for early stage Non-Small Cell Lung Carcinoma (NSCLC)

Kan¹

View full text Add to dashboard Cite

Lung cancer is currently the leading cause of cancer death in both developing and developed countries [1]. Given that lung cancer has poor prognosis in later stages, it is essential to achieve an early diagnosis to maximise a patient's overall survival [2]. Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), has the highest incidence in both smokers and non-smokers [3]. Therefore, there is an urgent need to develop methods to provide both sensitive and specific lung cancer diagnosis. The current standard and non-invasive screening method, low-dose computed tomography (LDCT), is the only radiological method which shows to have mortality benefits from multiple large randomized clinical trials (RCT) [4, 5]. However, these RCTs also found LDCT to have a significant false positive rate of 96% [4, 5] which resulted in unnecessary invasive biopsies being I recognize that the thesis be made available for research and studies in accordance with the Copyright Act 1968 unless a period embargo has been approved by the Dean of the Graduate School. This work also subjects to the policy and procedure of The University of Queensland. I acknowledge an electronic copy of my thesis must be lodged with the University Library. All uses of copyrighted material contained and used in this thesis have been permitted by their copyright holder(s) and have sought permission from co-authors for any jointly authored works. All copyrighted material belongs to their copyright holder(s).

show abstract

Circulating Tumor Cell Detection in Lung Cancer: But to What End?

Cited by 22 publications

References 108 publications

Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer

Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer

The value of circulating tumor cells with positive centromere probe 8 in the diagnosis of small pulmonary nodules.

Identification of clinically useful plasma miRNA as minimally invasive biomarkers for early stage Non-Small Cell Lung Carcinoma (NSCLC)

Contact Info

Product

Resources

About